PharmaShots | Incisive News in 3 Shots

Subscribe Now

HIV

PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV

PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV

April 26, 2022

Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV

Gilead Reports Interim Results of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in BICSTaR Study to Treat HIV

November 1, 2021

ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021

ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at I...

September 29, 2021

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

September 28, 2021

Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021

Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021

July 21, 2021

Gilead Reports New Data of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV

Gilead Reports New Data of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV

July 19, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us